For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

Publications

2018

TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis., P.M. Dominguez; H. Ghamlouch; W. Rosikiewicz; P. Kumar; W. Béguelin; L. Fontan; M.A. Rivas; P. Pawlikowska; M. Armand; E. Mouly; M. Torres-Martin; A.S. Doane; M.T.Calvo Fernández; M. Durant; V. Della-Valle; M. Teater; L. Cimmino; N. Droin; S. Tadros; S. Motanagh; A.H. Shih; M.A. Rubin; W. Tam; I. Aifantis; R.L. Levine; O. Elemento; G. Inghirami; M.R. Green; M.E. Figueroa; O.A. Bernard; S. Aoufouchi; S. Li; R. Shaknovich; A.M. Melnick, Cancer Discov, 2018 12, 8, 12, p.1632-1653, (2018) PubMed

Enhancer of zeste homolog 2 (EZH2) inhibitors., N. Gulati; W. Béguelin; L. Giulino-Roth, Leuk Lymphoma, 2018 07, 59, 7, p.1574-1585, (2018) PubMed

Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity., H. Kunimoto; C. Meydan; A. Nazir; J. Whitfield; K. Shank; F. Rapaport; R. Maher; E. Pronier; S.C. Meyer; F.E. Garrett-Bakelman; M. Tallman; A. Melnick; R.L. Levine; A.H. Shih, Cancer Cell, 2018 01 08, 33, 1, p.44-59.e8, (2018) PubMed

MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia., F.C. Brown; E. Still; R.P. Koche; C.Y. Yim; S. Takao; P. Cifani; C. Reed; S. Gunasekera; S.B. Ficarro; P. Romanienko; W. Mark; C. McCarthy; E. de Stanchina; M. Gönen; V. Seshan; P. Bhola; C. O'Donnell; B. Spitzer; C. Stutzke; V.P. Lavallée; J. Hébert; A.V. Krivtsov; A. Melnick; E.M. Paietta; M.S. Tallman; A. Letai; G. Sauvageau; G. Pouliot; R. Levine; J.A. Marto; S.A. Armstrong; A. Kentsis, Cancer Discov, 2018 04, 8, 4, p.478-497, (2018) PubMed

Identification of Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design., H. Cheng; B.M. Linhares; W. Yu; M.G. Cardenas; Y. Ai; W. Jiang; A. Winkler; S. Cohen; A. Melnick; A. MacKerell; T. Cierpicki; F. Xue, J Med Chem, 2018 09 13, 61, 17, p.7573-7588, (2018) PubMed

Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis., E. Pronier; R.L. Bowman; J. Ahn; J. Glass; C. Kandoth; T.R. Merlinsky; J.T. Whitfield; B.H. Durham; A. Gruet; A.Varshini H. Somasundara; R. Rampal; A. Melnick; R.P. Koche; B.S. Taylor; R.L. Levine, Blood, 2018 09 20, 132, 12, p.1265-1278, (2018) PubMed

AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis., M. Teater; P.M. Dominguez; D. Redmond; Z. Chen; D. Ennishi; D.W. Scott; L. Cimmino; P. Ghione; J. Chaudhuri; R.D. Gascoyne; I. Aifantis; G. Inghirami; O. Elemento; A. Melnick; R. Shaknovich, Nat Commun, 2018 01 15, 9, 1, p.222, (2018) PubMed

ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia., T. Maes; C. Mascaró; I. Tirapu; A. Estiarte; F. Ciceri; S. Lunardi; N. Guibourt; A. Perdones; M.M.P. Lufino; T.C.P. Somervaille; D.H. Wiseman; C. Duy; A. Melnick; C. Willekens; A. Ortega; M. Martinell; N. Valls; G. Kurz; M. Fyfe; J.Cesar Castro-Palomino; C. Buesa, Cancer Cell, 2018 03 12, 33, 3, p.495-511.e12, (2018) PubMed

Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth., L. Fontan; Q. Qiao; J.M. Hatcher; G. Casalena; I. Us; M. Teater; M. Durant; G. Du; M. Xia; N. Bilchuk; S. Chennamadhavuni; G. Palladino; G. Inghirami; U. Philippar; H. Wu; D.A. Scott; N.S. Gray; A. Melnick, J Clin Invest, 2018 10 01, 128, 10, p.4397-4412, (2018) PubMed

PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival., X. Lu; T.M. Fernando; C. Lossos; N. Yusufova; F. Liu; L. Fontan; M. Durant; H. Geng; J. Melnick; Y. Luo; F. Vega; V. Moy; G. Inghirami; S. Nimer; A.M. Melnick; I.S. Lossos, Blood, 2018 11 08, 132, 19, p.2026-2039, (2018) PubMed